Wedbush Raises Blueprint Medicines' Price Target to $120 From $110 After Stronger-Than-Expected Q1 Results, Keeps Outperform Rating
Wedbush Raises Blueprint Medicines' Price Target to $120 From $110 After Stronger-Than-Expected Q1 Results, Keeps Outperform Rating
在第一季度業績強於預期之後,Wedbush將Blueprint Medicines的目標股價從110美元上調至120美元,維持跑贏大盤的評級
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登入免費觀看全文
登入/註冊